StreetAlpha
13F holdings · Q3 2026

GSK

London, X0 · files as GSK plc
Know the moment GSK filesYou follow GSK An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 5, 2026Next filing due Feb 15, 2027CIK 1131399

GSK reported 13 stocks worth $497M in its 13F filing for Q3 2026, filed Nov 5, 2026. Its largest holdings are CRSP (29.0%), VIR (19.2%) and WVE (13.6%). Compared with Q2 2026, the fund opened new positions in WVE, trimmed CRSP and BNTX and sold out of WVE.

Latest filing: what GSK did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
1 new0 added2 trimmed1 sold outBought about $67.5M · sold about $162M
New 1
Added 0

None

Trimmed 2
Sold out 1

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$497M−17.5% vs last quarter
Stocks held131 new · 1 sold out
Top 5 weight85.4%very concentrated
Turnover46%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
CRSP
Crispr Therapeutics
$144M29.0%2.6M−612K (−19%)4 of 4
2
VIR
Vir Biotechnology Inc
$95.6M19.2%8.6MNo change4 of 4
3
WVE
Wave Life Sciences Inc.
$67.5M13.6%18.2MNew position1 of 4
4
BNTX
Biontech SE
$65.7M13.2%669K−221K (−25%)4 of 4
5
IDYA
Ideaya Biosciences Inc
$51.2M10.3%1.3MNo change4 of 4
6
CYTK
Cytokinetics Inc
$22.4M4.5%340KNo change4 of 4
7
LYEL
Lyell Immunopharma Inc
$14.8M3.0%1.5MNo change4 of 4
8
SPRO
Spero Therapeutics Inc
$11.1M2.2%9.2MNo change4 of 4
9
NKTX
Nkarta Inc
$8.3M1.7%3.2MNo change4 of 4
10
FULC
Fulcrum Therapeutics Inc
$6.6M1.3%1.8MNo change4 of 4
🔒 3 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
WVE
Wave Life Sciences Ltd
$106M18.2M

Reported value

last 4 quarters
$799MQ4 '25
$599MQ1 '26
$602MQ2 '26
$497MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 5, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

GSK 13F FAQ

What does GSK own?

GSK reported 13 stocks worth $497M in its 13F filing for Q3 2026, filed Nov 5, 2026. Its largest holdings are CRSP (29.0%), VIR (19.2%) and WVE (13.6%). The table above lists every position in the filing (the top 10 without an account).

What did GSK buy and sell in Q3 2026?

Compared with Q2 2026: 1 new positions, 0 added to, 2 trimmed and 1 sold out. New positions include WVE. It sold all of WVE.

When will GSK file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is GSK's portfolio worth?

The Q3 2026 filing reports $497M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.